Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2005

View Archived Issues

PET scans may help predict response to therapy in metastatic breast cancer

Inhaled insulin shows promise as an alternative to subcutaneous insulin in type 1 diabetes

Novartis reflects on Q2 activities

Thymitaq phase III study fails to meet primary endpoint

Phase IIb studies begin for PT-141 for erectile dysfunction

Two more sites join Canadian phase II study of ADH-1

Par terminates amoxicillin partnership with Advancis

Characterization of a novel VRAC inhibitor for heart disease

KBMA vaccines: novel strategy for safe protective immunity

SB-706375: novel nonpeptidic UT receptor antagonist

Antithrombotic activity of DU-176b described in several animal models

Data describing pharmacodynamic profile of TGN-255 presented

Biogen Idec and PDL form collaboration for antibody products

Novel immunomodulatory agents disclosed in recent patents

Novel agents for thrombotic disorders prepared and tested

Novel agents for treating ADHD in early development at PsychoGenics

Novel MRI agents imparted by General Hospital Corporation

Santhera and Takeda to collaborate on idebenone for Friedreich's ataxia

Pozen discontinues MT-100 development in U.S. following FDA review

Pozen submits Trexima NDA for migraine

HIV protease inhibitors have potential efficacy against opportunistic leishmaniasis infections

European orphan drug status recommended for Amplimexon

Rohto to acquire Bayer Yakuhin research center

AstraZeneca and Astex Therapeutics partner on PKB inhibitors for cancer

ISIS-301012 reduces LDL cholesterol in phase I study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...